相关实验视频

Updated: Jun 5, 2025

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

频繁增加MCL1的副本数量是骨髓瘤治疗的治疗点

Satoshi Takagi¹, Mikako Nakajima^1,2, Sumie Koike¹

¹Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research (JFCR), Tokyo, Japan.

|December 11, 2024

概括

恶性骨瘤 (骨肉瘤) 经常显示MCL1基因放大,使它们易受Mcl-1抑制剂的影响. 将这些与IGF-1R抑制剂相结合,显示出治疗骨髓瘤的前景.

科学领域:

在瘤学瘤学.
遗传学遗传学是一个
分子生物学分子生物学

背景情况:

骨髓瘤 (OS) 是一种主要的骨癌,影响儿童和青少年.
在OS药物开发方面取得的有限进展源于缺乏已识别的常见瘤驱动因素.
确定可操作的目标对于推进OS治疗至关重要.

研究的目的:

为了研究MCL1基因拷贝数改变在骨髓瘤中的作用.
评估Mcl-1抑制剂在MCL1-增强OS中的治疗潜力.
探索针对MCL1和IGF-1R通路的组合疗法.

主要方法:

在41个OS标本中检测MCL1放大现场光杂交 (FISH).
在OS细胞中,MCL1的遗传和药理抑制.
结合Mcl-1和IGF-1R抑制剂的组合治疗在体外和OS异种移植模型中的评估.

主要成果:

在46.3%的OS患者中发现了MCL1放大.
遗传性MCL1抑制诱导了扩大OS细胞的显著亡.
Mcl-1 抑制剂的治疗疗效与 MCL1 副本数相关.
同时准MCL1和IGF-1R协同诱导细胞死亡和抑制瘤生长.
观察到1q21.2-3区域的基因共同放大,包括IGF-1R/PI3K通路中的基因.

结论:

MCL1的基因组放大是骨髓瘤中经常发生的事件.
MCL1放大作为Mcl-1抑制剂治疗的预测生物标志物.
与Mcl-1和IGF-1R抑制剂的联合疗法在MCL1-增强的OS中显示出协同效果.
针对MCL1/IGF-1R轴为大量骨髓瘤患者提供了一个有前途的治疗策略.

更多相关视频

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells

Published on: September 1, 2019

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...